Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
暂无分享,去创建一个
Elisa Rossi | Vienna Ludovini | Lucio Crino | Federico Cappuzzo | Stefania Bartolini | Vanesa Gregorc | F. Cappuzzo | F. Hirsch | P. Bunn | W. Franklin | M. Varella‐Garcia | L. Crinò | M. Tonato | G. Ceresoli | K. Danenberg | C. Doglioni | V. Ludovini | E. Rossi | S. Bartolini | L. Bemis | Fred R Hirsch | Wilbur A Franklin | Paul A Bunn | Claudio Doglioni | Marileila Varella-Garcia | Giovanni L Ceresoli | Lynne Bemis | Jerry Haney | Samir Witta | Kathleen Danenberg | Irene Domenichini | Elisabetta Magrini | Angelo Sidoni | Maurizio Tonato | J. Haney | V. Gregorc | A. Sidoni | S. Witta | E. Magrini | I. Domenichini | M. Varella-Garcia | F. Hirsch
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] F. Cappuzzo,et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[4] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[5] J. Minna,et al. A chemical mismatch cleavage method useful for the detection of point mutations in the p53 gene in lung cancer. , 1990, American journal of respiratory cell and molecular biology.
[6] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[7] M. Kris,et al. O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone , 2003 .
[8] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[9] G. Giaccone,et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] M. Levitt,et al. Tyrosine Kinase Inhibitors in Preclinical Development , 2004, Investigational New Drugs.
[11] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.
[12] J. Crowley,et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[14] A. Santoro,et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer , 2004, British Journal of Cancer.
[15] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[16] Y. Shimosato,et al. Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.
[17] Matthew Meyerson,et al. Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255 , 2004, Cancer Research.
[18] S. R. Datta,et al. Cellular survival: a play in three Akts. , 1999, Genes & development.
[19] M. Rudnicki,et al. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[20] G. Tortora,et al. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Levitzki,et al. Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.
[23] G. Mills,et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.
[24] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[25] D. Parkin,et al. Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.
[26] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[27] C. Arteaga. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. , 2002, Seminars in oncology.
[28] M. Kuwano,et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. , 2004, Molecular cancer therapeutics.
[29] G. Bepler,et al. Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.
[30] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] William J. Gullick,et al. The erbB family of receptors and their ligands: multiple targets for therapy. , 2001 .
[32] F. Cappuzzo,et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. , 2004, Journal of the National Cancer Institute.
[33] G. Scagliotti,et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. , 2003, Lung cancer.
[34] J. Mattick,et al. 'Touchdown' PCR to circumvent spurious priming during gene amplification. , 1991, Nucleic acids research.
[35] O. Brodin,et al. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .
[36] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[37] A. Bezjak,et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial , 2004 .
[38] William Pao,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] D. Cox. Regression Models and Life-Tables , 1972 .
[40] M. Kris,et al. 54 The epidermal growth factor receptor tyrosine kinase inhibitor, eriotinib (Tarceva TM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: interim results of a phase II trial , 2003 .
[41] J. Rigas,et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.